SCHEMBL3567229

SCHEMBL3567229

CN(C)c1noc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 12/20 0.40
▸ CNR2 P34972 11/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MAPT P10636 1/20 0.37
▸ GABRA1 P14867 2/20 0.34
▸ ADRA2C P18825 2/20 0.34
▸ SLC6A3 Q01959 2/20 0.34
▸ EGFR P00533 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ MAPK3 P27361 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ SLC18A2 Q05940 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ TMEM97 Q5BJF2 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577543 0.88 KDM4E (0.41) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL1380418 0.87 KDM4E (0.41) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL3560867 0.82 CNR1 (0.42) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL1339468 0.80 KDM4E (0.41) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL1339427 0.80 CNR1 (0.38) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL3629309 0.80 CNR1 (0.40) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL3574329 0.79 HSD17B10 (0.42) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL1338174 0.79 CSF1R (0.38) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL1338764 0.79 BRD4 (0.41) CNR1CNR2ALDH1A1HSD17B10KDM4E
SCHEMBL3571986 0.79 CNR1 (0.37) CNR1CNR2ALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD CNR1 387/4885CNR2 448/4885ALDH1A1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback